Trial Profile

A Randomized, Placebo-controlled Phase II Trial Investigating SUNITINIB Versus Placebo in Patients With Chemorefractory Advanced Adenocarcinoma of the Stomach or Lower Esophagus Treated With Chemotherapy FOLFIRI.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 10 Apr 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Mar 2018 Results (n=54) assessing efficacy, safety, and tolerability of sunitinib as an adjunct to second- and third-line leucovorin (Cafolinate), 5-FU, and irinotecan (FOLFIRI), were published in the Tumour Biology.
04 Jun 2013 Results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
11 Jun 2012 Status changed from active, no longer recruiting to completed as reported by EudraCT.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com